证券代码：600998 证券简称：九州通 公告编号：临 2025-051 九州通医药集团股份有限公司 关于股东提前解除股份质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●公司股东中山广银办理完成51,729,000股的股份提前解除质押手续，公司股东上海 弘康办理完成58,000,000股的股份解除质押手续，本次解除质押股份占其所持股份的比 例分别为15.43%和5.33%，占公司总股本的比例分别为1.03%和1.15%。另外，上海弘康 办理完成64,110,000股的股份质押手续，本次质押股份占其所持股份的比例为5.89%，占 公司总股本的比例为1.27%。 ●公司股东中山广银和上海弘康分别持有公司股份335,357,275股和1,088,326,782股， 占公司总股本的比例分别为6.65%和21.58%。本次股份提前解除质押及质押办理完成后， 中山广银和上海弘康分别累计质押公司股份188,696,820股和539,571,892股，占其所持股 份的比例分别为56.27%和49.58%，占 ...

Group 1 - The core index of the China Securities Index for Food and Major Consumer Goods Retail has shown a decline of 2.40% over the past month, 6.58% over the past three months, and 6.48% year-to-date [1] - The index is composed of listed companies in the food and drug retail sector, reflecting the overall performance of these companies, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the index include Yonghui Supermarket (6.61%), Digital China (6.21%), Wancheng Group (4.68%), Shanghai Pharmaceuticals (4.41%), Yifeng Pharmacy (4.32%), Jiuzhoutong (3.86%), Kidswant (3.41%), Sinopharm (3.25%), Wangfujing (3.17%), and TianKang (3.09%) [1] Group 2 - The market segments represented in the index include 43.94% in pharmaceutical commerce, 21.32% in supermarkets and convenience stores, 20.29% in specialty retail, and 14.46% in department stores [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

Core Viewpoint - The article outlines the management measures for the employee stock ownership plan (ESOP) of Jiuzhoutong Pharmaceutical Group Co., Ltd. for the period 2023-2026, emphasizing compliance, voluntary participation, and risk-bearing principles. Group 1: General Principles - The ESOP will be implemented in strict accordance with relevant laws and regulations, ensuring accurate and timely information disclosure [1][2] - Participation in the ESOP is voluntary, with no forced allocation or distribution to employees [2] Group 2: Plan Implementation Procedures - The company will solicit employee opinions through representative meetings before implementing the ESOP [3] - The board of directors must approve the ESOP draft and ensure that related directors abstain from voting [3][4] - A legal opinion will be obtained before the shareholders' meeting to review the ESOP [4] - The shareholders' meeting will vote on the ESOP using a combination of on-site and online voting methods [4] Group 3: Funding and Stock Sources - The total amount of funds to be raised for the ESOP is approximately 461.69 million yuan, with each share priced at 1 yuan [5] - The ESOP will acquire stocks from the company's repurchase account and through market purchases [5] - The total scale of the ESOP is planned to be around 48.60 million shares, accounting for approximately 2.59% of the company's total share capital [5] Group 4: Lock-up Period and Performance Assessment - The lock-up period for the ESOP shares is set at 12 months from the distribution date of each batch [6][7] - Performance assessments will determine the returns for participants based on individual performance ratings [7] Group 5: Management Structure - The ESOP will be managed by a management committee elected by the participants, which will oversee daily operations and asset management [8][9] - The management committee is responsible for making decisions regarding the sale and distribution of the ESOP's assets [9] Group 6: Rights and Obligations of Participants - Participants have the right to request cash distributions or stock transfers after the lock-up period [14] - Participants are obligated to comply with the management committee's decisions regarding the ESOP [14][15]

第二条 九州通医药集团股份有限公司（以下简称"公司"）系依照《公司 法》和其他有关规定成立的股份有限公司。 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）和其他有关规定，制定本章程。 公司经湖北省商务厅（鄂商资【2008】133 号文）批准，在九州通集团有限 责任公司的基础上以整体变更方式发起设立。公司在湖北省市场监督管理局注册 登记，取得营业执照，统一社会信用代码为 9142000071451795XA。 第三条 公司于【2010 年 10 月 14 日】经中国证券监督管理委员会（以下简 称"中国证监会"）核准，首次向社会公众发行人民币普通股【150,000,000】股， 于【2010 年 11 月 2 日】在【上海证券交易所】上市。 公司于【2024 年 7 月 5 日】经中国证监会核准，公司向特定对象发行优先 九州通医药集团股份有限公司 章程 （2025 年 6 月修订） 目 录 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三 ...

| 北京海润天睿律师事务所 | | --- | | 关于九州通医药集团股份有限公司 | | 修订 2023-2025 年员工持股计划（草案）及第三批分 | | 配的 | | 法律意见书 | | 中国·北京 | | 朝阳区建外大街甲 14 号广播大厦 17 层 邮政编码：100022 | | 电话：(010)65219696 传真:(010)88381869 | | 二〇二五年六月 | | 释义 | | 在本法律意见书中，除非文义另有所指，下列词语具有下述含义： | | 九州通、公司 指 九州通医药集团股份有限公司 | | 《九州通医药集团股份有限公司 2023-2025 年员工持股 | | 《员工持股计划（草案）》 指 | | 计划（草案）》 | | 《员工持股计划（草案修 《九州通医药集团股份有限公司 2023-2026 年员工持股 | | 指 | | 订稿）》 计划（草案）（修订稿）》 | | 2023-2025 九州通医药集团股份有限公司 年员工持股计 | | 本次员工持股计划 指 划（本次名称拟修订为九州通医药集团股份有限公司 | | 九州通医药集团股份有限公司拟修订 2023-2025 年员工 | ...

Core Viewpoint - The company has revised its employee stock ownership plan for 2023-2025, extending it to 2023-2026 and adjusting the distribution batches and proportions to enhance implementation and compliance with regulatory guidelines [1][4][5] Summary by Sections Employee Stock Ownership Plan Overview - The company established the employee stock ownership plan in meetings held on April 26, 2023, and May 19, 2023, with the first two batches already implemented in 2023 and 2024 [1][2] Revision Details - The plan's distribution has been adjusted from three batches (2023-2025) to four batches (2023-2026), with the distribution proportions revised accordingly [2][3] - The first batch in 2023 allocated up to 17.5 million shares at a subscription price of 9.50 CNY per share, while the second batch in 2024 will allocate up to 30 million shares at a price of 5.00 CNY per share [2] Procedural Changes - The approval process for the employee stock ownership plan has been updated to align with new regulatory requirements, changing the announcement procedures and terminology from "shareholders' meeting" to "shareholders' assembly" [3][4] Impact of Revisions - The revisions are expected to facilitate the ongoing implementation of the employee stock ownership plan and comply with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [4][5] Legal Opinions - Legal counsel has confirmed that the revisions and the third batch distribution have received necessary approvals and comply with applicable laws and regulations [5]

九州通医药集团股份有限公司 关于增加经营范围暨修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 届董事会第十五次会议，审议通过了《关于公司增加经营范围暨修订 <公司章程> 的 议案》；因公司业务经营范围拓展的需要，依照企业经营范围登记管理规范性要求， 公司拟增加"装卸搬运、仓储服务、物流辅助服务、餐饮服务、教育培训服务、会 务服务、会议服务、企业管理服务、法律咨询、文化创意服务、健康管理服务费、 市场推广宣传、营销策划服务、企业运营管理服务、电子商务代运营"的经营范围。 同时，根据湖北省市场监督管理局的相关要求，结合公司实际情况，修订《公司章 程》相关条款，主要修订情况如下： 原条款 修订后条款 证券代码：600998 证券简称：九州通 公告编号：临 2025-049 第十五条 第十五条 经公司登记机关核准，公司经营范围是： 经公司登记机关核准，公司经营 许可项目：药品批发；危险化学品经营......一 范围是： 般项目：第一类医疗器械销售......地产中草药 许可项目：药品批发；危险化学 （不含中药饮 ...

证券代码：600998 证券简称：九州通 九州通医药集团股份有限公司 （草案）（修订稿） 九州通医药集团股份有限公司 二○二五年六月 一、九州通医药集团股份有限公司（以下简称"九州通"或"公司"）2023-2026 年员工持股计划（以下简称"本员工持股计划"）须经公司股东会批准后方可实 施，本员工持股计划能否获得公司股东会批准，存在不确定性； 二、本员工持股计划设立后将由公司自行管理，也可根据实际需要聘请外部 专业机构为本员工持股计划提供资产管理、咨询等服务；但能否达到计划规模、 目标存在不确定性； 三、有关本员工持股计划的具体的资金来源、出资金额、实施方案等属初步 结果，能否完成实施，存在不确定性； 四、若员工认购资金较低时，本员工持股计划存在不成立的风险； 五、股票价格受公司经营业绩、宏观经济周期、国际/国内政治经济形势及 投资者心理等多种复杂因素影响。因此，股票交易是有一定风险的投资活动，投 资者对此应有充分准备； 六、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 -2- 特别提示 声 明 本公司及公司董事会全体成员保证本员工持股计划不存在虚假记载、误导性 陈述或重大遗漏 ...

Core Points - The company held its 15th meeting of the 6th Board of Directors, where several key resolutions were passed to enhance corporate governance and employee engagement [1][2][5] Group 1: Board Resolutions - The company approved the election of Ms. Wang Ying as a member of the Nomination and Remuneration Committee, effective immediately until the end of the current board term [1] - The board approved the revision of the 2023-2025 Employee Stock Ownership Plan (ESOP) to extend the distribution from three batches to four batches from 2023 to 2026, aligning with recent regulatory guidelines [2][3] - The board also approved the revision of the management rules for the Employee Stock Ownership Plan to reflect changes in distribution batches and ratios [3][4] Group 2: Employee Stock Ownership Plan - The company plans to initiate the third batch of the Employee Stock Ownership Plan for 2025, with a maximum participation of 300 individuals, including directors (excluding independent directors), senior management, and key technical staff [4] - The distribution amount for the third batch will be based on the company's previous capital increase plans, with a subscription price set at 3.60 yuan per share [4] Group 3: Dividend and Business Expansion - The company announced a dividend distribution plan for preferred shares, with a total payout of 89.5 million yuan based on a 5% dividend rate for the period from August 12, 2024, to August 11, 2025 [4] - The company proposed to expand its business scope to include logistics, catering, education, and various management services, which requires amendments to the company's articles of association [5]

证券代码：600998 证券简称：九州通 公告编号：临 2025-046 九州通医药集团股份有限公司关于 2023-2025 年员工持股计划第二次持有人会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 因员工持股计划后续实施的需要，依据2022年年度股东大会的授权，公司 拟对《九州通2023-2025年员工持股计划（草案）》及其摘要内容中的分配批次、 分配比例等内容进行修订和完善，并同步对《九州通员工持股计划管理办法》的 部分内容进行修订。 一、《关于公司修订2023-2025年员工持股计划（草案）及其摘要的议案》 因员工持股计划后续实施的需要，依据2022年年度股东大会的授权，公司拟 修订2023-2025年员工持股计划（草案）及其摘要，将原方案中的2023-2025年三 批次分配调整为2023-2026年四批次分配，并相应调整未实施分配批次的比例。 同时，为落实近期发布的《关于上市公司实施员工持股计划试点的指导意见（2025 年修订）》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》 等法规的规定 ...